| A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor J Giroud-Gerbetant, M Joffraud, MP Giner, A Cercillieux, S Bartova, ... Molecular metabolism 30, 192-202, 2019 | 131 | 2019 |
| Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice R Zapata‐Pérez, A Tammaro, BV Schomakers, AML Scantlebery, S Denis, ... The FASEB Journal 35 (4), e21456, 2021 | 68 | 2021 |
| Endogenous nicotinamide riboside metabolism protects against diet-induced liver damage A Sambeat, J Ratajczak, M Joffraud, JL Sanchez-Garcia, MP Giner, ... Nature communications 10 (1), 4291, 2019 | 50 | 2019 |
| CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative J Luque, I Mendes, B Gomez, B Morte, M López de Heredia, E Herreras, ... Clinical Genetics 101 (5-6), 481-493, 2022 | 14 | 2022 |
| Nicotinamide Riboside and Dihydronicotinic Acid Riboside Synergistically Increase Intracellular NAD+ by Generating Dihydronicotinamide Riboside E Ciarlo, M Joffraud, F Hayat, MP Giner, J Giroud-Gerbetant, ... Nutrients 14 (13), 2752, 2022 | 12 | 2022 |
| A reduced form of nicotinamide riboside defines a new path for NAD (+) biosynthesis and acts as an orally bioavailable NAD (+) precursor. Mol Metab 30: 192–202 J Giroud-Gerbetant, M Joffraud, MP Giner, A Cercillieux, S Bartova, ... Mech Ageing Dev 198 (111545), 84, 2019 | 7 | 2019 |
| Nicotinamide riboside kinase 1 protects against diet and age-induced pancreatic β-cell failure A Cercillieux, J Ratajczak, M Joffraud, JL Sanchez-Garcia, G Jacot, ... Molecular Metabolism 66, 101605, 2022 | 3 | 2022 |
| Erythropoietin supplementation ameliorates the immunological and hematological deficiencies of lysinuric protein intolerance in mice J Giroud-Gerbetant, F Sotillo, J Couso, A Zorzano, M Sanchez, G Weiss, ... bioRxiv 10 (2021.08), 15.456393, 2022 | 1 | 2022 |
| Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions CC Alvarez, S Christen, MP Giner, J Giroud-Gerbetant, M Joffraud, ... US Patent App. 17/905,262, 2023 | | 2023 |
| Reduced nicotinamideribosides for the treatment/prevention of liver disease CC Alvarez, S Christen, MP Giner, J Giroud-Gerbetant, S Moco, M Migaud US Patent App. 17/595,984, 2022 | | 2022 |
| Reduced nicotinamideribosides for treating or preventing kidney disease CC Alvarez, S Christen, MP Giner, J Giroud-Gerbetant, S Moco, S Bartova, ... US Patent App. 17/596,130, 2022 | | 2022 |
| Reduced nicotinamideribosides for treating/preventing skeletal muscle disease CC Alvarez, S Christen, MP Giner, J Giroud-Gerbetant, S Moco US Patent App. 17/595,945, 2022 | | 2022 |
| Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions CC Alvarez, S Christen, MP Giner, J Giroud-Gerbetant, M Sofia, ... | | 2021 |
| Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of viral and bacterial infections CC Alvarez, S Christen, MP Giner, J Giroud-Gerbetant, M Sofia, ... | | 2021 |
| Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of lung diseases and conditions CC Alvarez, S Christen, MP Giner, J Giroud-Gerbetant, M Sofia, ... | | 2021 |
| Defective Slc7a7 transport reduces erythropoietin compromising erythropoiesis and iron homeostasis J Giroud-Gerbetant, F Sotillo, G Hernández, CJ Lynch, I Ruano, B Siri, ... bioRxiv, 2021.08. 15.456393, 2021 | | 2021 |
